State insurance regulators are talking about what they say is misleading language in a proposed Medicare drug benefits notice.[@@]
The National Association of Insurance Commissioners, Kansas City, Mo., has outlined its concerns in a comment letter on the text of the proposed notice. The Centers for Medicare and Medicaid Services would send the notice to senior citizens and other Medicare beneficiaries to tell them about the new Medicare Part D drug benefits.
CMS used most of the content from an NAIC draft notice, but it made important changes to the draft, NAIC regulators write in the letter, which is addressed to CMS officials.
The CMS proposal “adds what the NAIC believes to be misleading language in an attempt to persuade beneficiaries to enroll in Medicare Part D,” the regulators write. “The proposed notice makes generalized, subjective judgments regarding the relative value of the enrollees’ current Medigap plan when compared to the new Part D.”
The NAIC letter was signed by Kansas Insurance Commissioner Sandy Praeger, who also chairs the NAIC’s Health Insurance and Managed Care (B) Committee.
The current CMS version of the drug benefit disclosure statement says the new Part D plan will “provide greater value,” the regulators write.